100 related articles for article (PubMed ID: 1941062)
1. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Trump DL; Egorin MJ; Forrest A; Willson JK; Remick S; Tutsch KD
J Clin Oncol; 1991 Nov; 9(11):2027-35. PubMed ID: 1941062
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
Remick SC; Grem JL; Fischer PH; Tutsch KD; Alberti DB; Nieting LM; Tombes MB; Bruggink J; Willson JK; Trump DL
Cancer Res; 1990 May; 50(9):2667-72. PubMed ID: 2328492
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
4. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.
Danhauser LL; Freimann JH; Gilchrist TL; Gutterman JU; Hunter CY; Yeomans AC; Markowitz AB
J Clin Oncol; 1993 Apr; 11(4):751-61. PubMed ID: 8478667
[TBL] [Abstract][Full Text] [Related]
5. Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
Zalupski MM; Baker LH
J Infus Chemother; 1995; 5(3):129-31. PubMed ID: 8528970
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
[TBL] [Abstract][Full Text] [Related]
9. Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Grunberg SM; Clay C; Spicer DV
Sel Cancer Ther; 1991; 7(1):17-21. PubMed ID: 1833803
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
[TBL] [Abstract][Full Text] [Related]
15. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?
Boos J; Krümpelmann S; Schulze-Westhoff P; Euting T; Berthold F; Jürgens H
J Clin Oncol; 1995 Dec; 13(12):2954-60. PubMed ID: 8523060
[TBL] [Abstract][Full Text] [Related]
16. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Chiara S; Nobile MT; Vincenti M; Lionetto R; Gozza A; Barzacchi MC; Sanguineti O; Repetto L; Rosso R
Cancer Chemother Pharmacol; 1998; 42(4):336-40. PubMed ID: 9744780
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents.
Ogino M; Minoura S
Int J Clin Oncol; 2001 Apr; 6(2):84-9. PubMed ID: 11706755
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid.
Budd GT; Jayaraj A; Grabowski D; Adelstein D; Bauer L; Boyett J; Bukowski R; Murthy S; Weick J
Cancer Res; 1990 Nov; 50(22):7206-11. PubMed ID: 2224854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
